ClinicalTrialsFinder

HR+/HER2- Early Breast Cancer Clinical Trials in Nanjing, Jiangsu

1 recruitingNanjing, Jiangsu, China

Showing 1–1 of 1 trials

Recruiting
Phase 2

Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer

HR+/HER2- Early Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University100 enrolled3 locationsNCT07616427